Treatment of Carrying TP53 Harmful Mutations

Inclusion Criteria:

* Age is 18≥years ≤70 years .
* ECOG body State is 0\~1 score.
* The estimated survival period are greater than 3 months .
* Histologic or cytological diagnosis of advanced refractory tumors that are ineffective or without standard treatment by standard multi-line therapy. The definition of treatment invalidity: progression of disease after multiple line therapy.
* With the relevant qualification agencies NGS (second generation sequencing) report, and the molecular Oncology Expert Committee identified TP53 as the main harmful mutation.
* The patient has at least one measurable lesion that can be assessed by CT or MRI (RECIST 1.1).
* Previous treatment of any anti-tumor therapy (including radiotherapy, chemotherapy, hormone therapy, surgery, or molecular targeting therapy) ended with the Thou Yan ≥4 weeks (to the first medication) in this trial.
* Urine routine display urine protein \<2+, if urine protein qualitative ≥2+, should accept 24 hour urine protein quantitative detection, ≤ 1g can be entered into a group.
* Good organ function level ( no blood transfusion, no use of G-CSF in the first 7 days of screening ; no drug correction;7 days without loss ALB):ANC≥ 1.5x109/L;WBC≥ 3x109 /L;PLT≥80x109/L ;Hb≥90g/l; TBIL≤1.5xULN;ALT and AST≤2.5xULN; ALB≥29g/l ;BUN and Cr ≤1. 5xULN ;LVEF ≥50%;Fridericia method to correct QT Inter-period (QTcF ) Male \<450 ms , Women \<470 ms .
* Women of childbearing age are required to take effective contraceptive measures at least 8 weeks after taking part in the study and after the last drug delivery .
* Can follow the test plan according to the judgment of the investigator.
* Volunteer to participate in this clinical trial, have the ability to understand the research requirements, can give written informed consent.

Exclusion Criteria:

* Anticancer drugs, including Fluzoparib that used or were using PARP as a target.
* Antineoplastic agents used or using VEGFR targets, including Apatinib.
* As a participant in the clinical trial, and the signing of the informed consent of the last clinical trial at the end of the interval of less than days.
* Has a blood system-related tumor.
* Receive any anti-tumor treatment (including radiotherapy, chemotherapy, hormone therapy, surgery or molecular targeting therapy) within 4 weeks before delivery;
* Double phosphate drug treatment was received in the first 4 weeks of the drug delivery;
* There is a CTCAE grade II toxicity caused by previous treatment.
* Hypertension is not controlled (systolic pressure is greater than 150mmHg, or diastolic pressure is greater than 90 mmHg); or a history of congestive heart failure (American Heart Association heart function grade ≥2 Level).
* Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, arrhythmia, myocardial infarction, QTc period ≥470ms.
* Intestinal obstruction or CTCAE 3 or 4 upper digestive tract bleeding in the first 4 weeks before the drug delivery.
* Inability to swallow, inflammatory bowel disease or uncontrollable nausea, vomiting, diarrhea or other gastrointestinal disorders that seriously affect drug use and absorption.
* The tumor metastasis of central nervous system was diagnosed by the researchers.
* A history of severe venous thrombosis or pulmonary embolism.
* There is a third interstitial fluid (such as large pleural effusion and ascites) that cannot be controlled by drainage or other means.
* There is still an electrolyte disorder that cannot be corrected when the group is given a drug.
* In the first 7 days before the group received a strong CYP3A4 inhibitor treatment, or in the first day of the group received a strong effect CYP3A4 Inducer therapy.
* Active HBV, HCV infection (HBV copy number ≥104 copies/ml, the number of copies of HCV virus ≥103 copies /ml).
* There is a history of immune deficiency, including HIV testing positive, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.
* Pregnancy, breast-feeding female patients.
* In patients with bone metastases, palliative radiotherapy (radiotherapy area,5% bone marrow region) was received within 4 weeks before the group's entry.
* According to the researchers ' judgment, there are serious, uncontrollable risks to patients ' safety, or associated diseases (such as severe diabetes, thyroid disease, infection, spinal cord compression, superior vena cava syndrome, neurological or psychiatric disorders) that affect the patient's completion of the study.